Elanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs
Elanco received USDA approval for TruCan Ultra Lyme-L4, the first and only 1/2 mL combination vaccine protecting dogs against both Lyme disease and leptospirosis. The product leverages proprietary PureFil Technology to reduce vaccination reactions and minimizes injection volume, addressing a 40% protection gap in Lyme vaccination among at-risk dogs. With Leptospirosis now classified as a core vaccine by AAHA guidelines, the combination format offers a competitive advantage in convenience and compliance.
Key figures
- Drug Name
- TruCan Ultra Lyme-L4
- Lyme efficacy lab
- 100%
- Protection gap pct
- 40%
- Lyme efficacy natural
- 92.2%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.